Indivior Pharmaceuticals, Inc.·4

Jan 28, 4:10 PM ET

Ryan Barbara 4

Research Summary

AI-generated summary

Updated

Indivior (INDV) Director Ryan Barbara Receives RSU Award

What Happened

  • Ryan Barbara, a director of Indivior Pharmaceuticals (INDV), was granted 3,722 Restricted Stock Units (RSUs) on January 26, 2026. The grant price is listed as $0.00 (no cash exchanged at grant); each RSU represents a contingent right to receive one share of Indivior common stock upon vesting.

Key Details

  • Transaction date: 2026-01-26; Grant type: Award/Acquisition (A); Shares granted: 3,722; Price at grant: $0.00.
  • Vesting: RSUs vest on the day immediately preceding the date of the first annual meeting of stockholders following the grant, subject to the reporting person’s continued service (see footnote).
  • Filing: Form 4 filed 2026-01-28 for the 2026-01-26 grant — appears timely under Form 4 rules.
  • Shares owned after the transaction: not disclosed in the provided filing summary.
  • No tax-withholding, sale, or 10b5-1 plan noted in the filing excerpt.

Context

  • RSUs are a promise to deliver shares in the future if vesting conditions are met; they are not an immediate purchase or sale and do not by themselves indicate a buy or sell signal. If and when the RSUs vest and convert to shares, tax withholding or subsequent sales could follow and would be reported separately.